

Can't find Besifloxacin (Besivance)? Here are proven alternative eye drops for bacterial conjunctivitis, including cost, availability, and what to ask your doctor.
Bacterial conjunctivitis — pinkeye — needs treatment, and it needs it soon. If your doctor prescribed Besifloxacin (brand name Besivance) and you can't find it at any pharmacy near you, don't panic. There are several effective alternatives that can treat your infection just as well.
Besifloxacin is a brand-name-only medication with known availability challenges. The good news is that other fluoroquinolone eye drops — many available as affordable generics — work through similar mechanisms and are widely stocked at pharmacies nationwide.
Here's everything you need to know about your options.
Besifloxacin is a fourth-generation fluoroquinolone antibiotic eye drop prescribed for bacterial conjunctivitis. It's available only as the brand-name product Besivance, manufactured by Bausch + Lomb, in a 0.6% ophthalmic suspension.
The medication works by targeting two essential bacterial enzymes — DNA gyrase and topoisomerase IV — which bacteria need to copy and repair their DNA. By blocking both enzymes simultaneously, Besifloxacin kills a broad range of bacteria that cause eye infections. For a deeper dive, read our article on how Besifloxacin works.
The standard treatment is one drop in the affected eye three times daily for seven days. It's effective, but it's not the only fluoroquinolone eye drop that works for pinkeye.
There are several common reasons patients end up needing a Besifloxacin substitute:
The following medications are commonly prescribed as alternatives to Besifloxacin. All are fluoroquinolone antibiotics that treat bacterial conjunctivitis, but they differ in generation, cost, availability, and dosing.
Moxifloxacin is the closest alternative to Besifloxacin. Like Besifloxacin, it's a fourth-generation fluoroquinolone that targets both DNA gyrase and topoisomerase IV, giving it broad-spectrum activity against common conjunctivitis-causing bacteria.
Moxifloxacin is often the first choice when Besifloxacin isn't available because it shares the same generation and similar spectrum of activity.
Ofloxacin is a second-generation fluoroquinolone that has been used for decades to treat bacterial eye infections. While it targets primarily DNA gyrase (rather than both enzymes), it remains effective against many common conjunctivitis pathogens.
Ciprofloxacin is another well-established second-generation fluoroquinolone available in both eye drop and ointment forms. The ointment option can be particularly useful for young children or patients who have difficulty with eye drops.
Gatifloxacin is a fourth-generation fluoroquinolone like Besifloxacin, offering dual-enzyme targeting and broad-spectrum coverage. It's available as the brand-name product Zymaxid.
If you can't find Besifloxacin, contact your prescriber's office and let them know. Here's what to say:
Most doctors can call in or e-prescribe an alternative within the same day, so you won't need another office visit.
Besifloxacin is an effective medication, but it's far from the only option for treating bacterial conjunctivitis. If you're struggling with availability or cost, generic Moxifloxacin is usually the closest substitute in terms of effectiveness, while Ofloxacin and Ciprofloxacin offer the most affordable options.
Before switching, always consult your doctor — they know your specific infection and medical history. And if you'd still prefer to fill your original Besifloxacin prescription, try using Medfinder to check which pharmacies near you have it in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.